Newsfeeds - Spark Newswire

1 minute read

G1 Therapeutics Q4 EPS $(0.94) Beats $(1.03) Estimate, Sales $5.80M Beat $5.68M Estimate

Today, 12:02 PM

G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.03) by 8.74 percent. This is a 40.3 percent decrease over losses of $(0.67) per share from the

GTHX

15 minute read

Earnings Scheduled For February 23, 2022

By Benzinga Insights

Today, 12:02 PM

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.

AAN

32 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 12:02 PM

On Thursday, 615 stocks hit new 52-week lows.

AAOI

2 minute read

G1 Therapeutics Announces Initiation Of New Phase 2 Trial Of Trilaciclib In Combination With The Antibody-Drug Conjugate, Trodelvy

By Benzinga Newsdesk

Today, 12:02 PM

G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib administered prior to the antibody-drug

GTHX

1 minute read

Analyst Ratings

Analyst Ratings For G1 Therapeutics

By Benzinga Insights

Today, 12:02 PM

Analysts have provided the following ratings for G1 Therapeutics (NASDAQ:GTHX) within the last quarter:

GTHX

1 minute read

JP Morgan Downgrades G1 Therapeutics to Underweight, Lowers Price Target to $19

By Benzinga Newsdesk

Today, 12:02 PM

JP Morgan analyst Anupam Rama downgrades G1 Therapeutics (NASDAQ:GTHX) from Neutral to Underweight and lowers the price target from $20 to $19.

GTHX

1 minute read

HC Wainwright & Co. Maintains Buy on G1 Therapeutics, Lowers Price Target to $71

By Benzinga Newsdesk

Today, 12:02 PM

HC Wainwright & Co. analyst Edward White maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $78 to $71.

GTHX

1 minute read

Raymond James Maintains Outperform on G1 Therapeutics, Lowers Price Target to $24

By Benzinga Newsdesk

Today, 12:02 PM

Raymond James analyst Dane Leone maintains G1 Therapeutics (NASDAQ:GTHX) with a Outperform and lowers the price target from $41 to $24.

GTHX

1 minute read

Recap: G1 Therapeutics Q3 Earnings

By Benzinga Insights

Today, 12:02 PM

G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

GTHX

25 minute read

Earnings Scheduled For November 3, 2021

By Benzinga Insights

Today, 12:02 PM

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.

AAWW